Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.

Guillermo Garcia-Manero,Antonio Almeida,Pierre Fenaux,Norbert Gattermann,Aristoteles Giagounidis,Stuart L Goldberg,Keiya Ozawa,Jerry Weaver,Valeria Santini

Clinical Lymphoma Myeloma and Leukemia（2019）

引用 3|浏览28

暂无评分

摘要

Despite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit.

查看译文

关键词

Adverse events,Benefit-risk ratio,Dose reduction,Response,Treatment exposure

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要